Christie Ballantyne, MD

home / authors / christie-ballantyne-md

Articles

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.

Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

The Role of Lipoprotein A in Lipid Lowering

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Long-term efficacy and safety of PCSK9 inhibitors

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

November 27th 2023

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

Starting Combination Therapy Early

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

October 5th 2023

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Nonstatin Lipid-Lowering Agents

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

October 5th 2023

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

Statin Intolerance

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 28th 2023

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.

Disparities in Managing Patients

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 28th 2023

Expert cardiologists discuss data on gender, racial, and ethnic disparities and how to address them in the management of hyperlipidemia.

LDL Cholesterol as a Performance Measure

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 21st 2023

The cardiology panelists discuss the importance of screening patients for hyperlipidemia and familial hypercholesterolemia.

Reasons for Not Reaching Thresholds

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 21st 2023

The reasons many patients do not reach LDL-cholesterol thresholds.

Real-World Outcomes Data on Failure to Achieve LDL-C Thresholds

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 14th 2023

Mary McGowan, MD, FNLA, reviews real-world data from the Family Heart Database on the clinical consequences of failing to reach LDL-C thresholds.

Real-World Data on Achieving LDL Thresholds

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 14th 2023

Mary McGowan, MD, FNLA, discusses real-world data from the Family Heart Database on achieving LDL-C thresholds.

New Guidance in Lowering LDL-C

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 7th 2023

A panel of cardiologists discuss the key updates from the 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease risk.

LDL-C and Cardiovascular Disease Risk

Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA;Erin D. Michos, MD, MHS;Christie Ballantyne, MD;Mary McGowan, MD, FNLA;Payal Kohli, MD, FACC

September 7th 2023

Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.

Future Directions for the Treatment of ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

June 6th 2022

Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Emerging Agents for Treatment of Hypercholesterolemia and ASCVD

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

June 6th 2022

Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.

ASCVD and Hypercholesterolemia: Patient Selection for Bempedoic Acid

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

June 6th 2022

Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Safety and Efficacy of Bempedoic Acid for ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 30th 2022

Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.

ASCVD and Hypercholesterolemia: Combination Therapy and Statin Intolerance

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 30th 2022

Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Role of Icosapent Ethyl in Managing ASCVD and Other Lipid Disorders

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 23rd 2022

Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.

Older Agents to Manage ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 23rd 2022

Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.

Bempedoic Acid to Manage ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 16th 2022

Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.

Managing ASCVD and Hypercholesterolemia: Statins, Ezetimibe, and PCSK9 Inhibitors

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 16th 2022

Matthew J. Budoff, MD; Erin D. Michos, MD, MHS; and Paul S. Jellinger, MD, MACE, discuss the role of statins, ezetimibe, and PSCK9 inhibitors for patients with ASCVD and hypercholesterolemia.

Implementing Lifestyle Modifications for ASCVD and Hypercholesterolemia Management

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 9th 2022

Christie Ballantyne, MD, and Erin D. Michos, MD, MHS, explore the impact of lifestyle changes on managing ASCVD and hypercholesterolemia.

DCRM Practice Recommendations for ASCVD and Metabolic Diseases

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 9th 2022

Expert endocrinologists and cardiologists review the role of DCRM multispecialty practice recommendations and the use of combination therapy for patients with ASCVD and hypercholesterolemia.

Utilizing Guideline Recommendations for ASCVD and Hypercholesterolemia Management

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 2nd 2022

Drs Erin D. Michos, Matthew J. Budoff, Paul S. Jellinger, and Yehuda Handelsman, share their approach to incorporating guideline recommendations for the management of patients with ASCVD and hypercholesterolemia in clinical practice.

Management of Patients With ASCVD and Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

May 2nd 2022

Dr Christie Ballantyne leads a discussion on how the management of patients with ASCVD and hypercholesterolemia has changed over the years.

Impact of Comorbidities on Atherosclerosis

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

April 25th 2022

Yehuda Handelsman, MD; Christie Ballantyne, MD; Paul S. Jellinger, MD, MACE; and Erin D. Michos, MD, MHS, comment on the impact of diabetes on chronic kidney disease and cardiovascular disease.

Prevalence and Risk Factors for ASCVD Associated With Hypercholesterolemia

Yehuda Handelsman, MD;Matthew J. Budoff, MD;Christie Ballantyne, MD;Erin D. Michos, MD, MHS;Paul S. Jellinger, MD, MACE

April 25th 2022

Matthew J. Budoff, MD; Christie Ballantyne, MD; and Paul S. Jellinger, MD, MACE, discuss the incidence and prevalence of atherosclerotic cardiovascular diseases (ASCVD) associated with hypercholesterolemia and risk factors for disease.